Welcome to our dedicated page for Milestone Pharmaceuticals SEC filings (Ticker: MIST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Milestone Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Milestone Pharmaceuticals's regulatory disclosures and financial reporting.
Milestone Pharmaceuticals Inc. (MIST) announced that China’s National Medical Products Administration has approved etripamil nasal spray for treatment of paroxysmal supraventricular tachycardia (PSVT) in adults, the first regulatory approval for etripamil outside the United States.
The approval triggers a $2.0 million payment to Milestone from partner Everest Medicines, which holds exclusive development and commercialization rights in Greater China. Milestone is also eligible for up to $98.0 million in additional commercial and development milestones and tiered royalties of up to 18% on future sales in Greater China. The decision was supported by Phase 3 data, including the JX02002 study in China, where etripamil was significantly superior to placebo in converting PSVT to sinus rhythm within 30 minutes.
Milestone Pharmaceuticals Inc. reported second-quarter 2026 results and business updates centered on the launch of CARDAMYST, its FDA-approved nasal spray for paroxysmal supraventricular tachycardia (PSVT). Product revenue was $559,000 for the quarter and $797,000 for the first six months of 2026, compared with no product revenue a year earlier.
Cash, cash equivalents and short-term investments totaled $170.6 million as of June 30, 2026, up from $106.0 million as of December 31, 2025, and the company expects this to fund operations into the second half of 2027. The quarterly net loss widened to $28.6 million, or $0.21 per share, from $13.0 million, or $0.20 per share, driven largely by a jump in selling, general and administrative expense to $22.6 million as the company supports the CARDAMYST launch.
Commercially, Milestone states that over half of commercially insured lives in the U.S. now have coverage for CARDAMYST. Internationally, European review of etripamil for PSVT is ongoing with a targeted decision in the first half of 2027, and a New Drug Application in China is under review. The Phase 3 ReVeRA-301 registrational trial of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR) is open, with several sites activated and patients being evaluated for enrollment.
Milestone Pharmaceuticals reported its first commercial sales of CARDAMYST (etripamil) nasal spray in the United States, generating $0.6 million in product revenue for the quarter and $0.8 million for the first half of 2026. The company remains focused on CARDAMYST’s PSVT launch, advancing etripamil for AFib-RVR, and ex-U.S. regulatory and partnering activities.
The business is still highly loss‑making: net loss was $28.6 million for the quarter and $54.7 million year‑to‑date, driven mainly by a sharp increase in selling, general and administrative expenses to $22.6 million in the quarter as commercialization ramps. Operating cash outflow for the first half was $38.8 million.
Liquidity is currently strong. As of June 30, 2026, Milestone held $170.6 million in cash, cash equivalents and short‑term investments, and recorded a royalty financing obligation of $81.8 million and senior secured convertible notes of $59.2 million. The company states that existing cash resources are expected to fund planned operations for at least the next 12 months.
Pavaki Capital Partners, LP, together with Pavaki Capital Management, LLC and Ashok Rambhai Patel, reports beneficial ownership of 9,067,848 common shares of Milestone Pharmaceuticals Inc. as of December 31, 2025. This position represents 7.3% of the company’s outstanding common shares.
The shares are held directly by Pavaki Capital Partners, LP, with Pavaki Capital Management, LLC acting as general partner and investment manager, and Ashok Rambhai Patel as managing member. The group reports 0 shares with sole voting or dispositive power and 9,067,848 shares with shared voting and shared dispositive power. Smita Ashok Ram LLC, as limited partner, has rights to dividends and sale proceeds in line with its partnership interest.
Milestone Pharmaceuticals Inc. reported results from its 2026 annual shareholder meeting. Shareholders approved an amendment to the 2019 Equity Incentive Plan that increases the number of ordinary shares authorized for issuance by 6,800,000 shares, expanding the pool available for future equity-based compensation.
All eight director nominees were elected, each receiving roughly 23.4–24.2 million votes for and about 3.1–3.9 million votes withheld, with 48.6 million broker non-votes recorded per nominee. Shareholders also ratified PricewaterhouseCoopers LLP as auditor with 75,025,285 votes for, 249,836 against and 664,912 abstentions.
They approved the amended 2019 Equity Incentive Plan with 19,262,773 votes for, 5,479,043 against, 2,617,059 abstentions and 48,581,158 broker non-votes. In a non-binding advisory vote on executive pay, 19,665,705 votes supported the compensation of named executive officers, 6,990,920 were against, 702,247 abstained and 48,581,161 were broker non-votes.
Milestone Pharmaceuticals Inc. director Lisa M. Giles received a grant of stock options covering 77,000 shares of common stock. The options have an exercise price of $1.2200 per share and expire on June 10, 2036. They vest in twelve equal monthly installments starting July 10, 2026, or will be fully vested by the next annual stockholder meeting if she continues providing service.
Milestone Pharmaceuticals director Seth H. Z. Fischer received a grant of stock options covering 77,000 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 10, 2036. They vest in twelve equal monthly installments starting July 10, 2026, or will be fully vested by the next annual stockholder meeting if he continues serving.
Milestone Pharmaceuticals Inc. director Duty Stuart received a grant of stock options covering 77,000 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 10, 2036. Following this grant, Stuart holds options on 77,000 shares.
The award vests in twelve equal monthly installments starting on July 10, 2026, and will in any case be fully vested on the date of the next annual stockholders’ meeting, as long as Stuart continues providing service through each vesting date.
Milestone Pharmaceuticals director Robert James Wills reported a grant of stock options for 77,000 shares of Common Stock. The options have an exercise price of $1.22 per share and expire on June 10, 2036. This is a compensation-related award, not an open-market purchase.
The option vests in twelve equal monthly installments beginning on July 10, 2026, and will in any case be fully vested on the date of the next annual meeting of stockholders, as long as Wills continues providing service through each vesting date. Following this grant, he holds 77,000 option-based rights directly.
Milestone Pharmaceuticals Inc. director Michael John Tomsicek received a grant of stock options covering 77,000 shares of common stock at an exercise price of $1.22 per share. The options vest in twelve equal monthly installments beginning on July 10, 2026, and will in any case be fully vested by the date of the next annual stockholders’ meeting, as long as he continues to provide service. Following this grant, he holds 77,000 stock options directly, which are scheduled to expire on June 10, 2036.